Eli Lilly's orforglipron outshines Novo Nordisk's oral semaglutide with efficacy & scalability, promising growth in obesity & diabetes markets.

The FDA approved updated Covid boosters but ended emergency authorizations in moves that could make the shots more difficult to obtain for kids under 5 ...

Novo Nordisk has brought on other cardiometabolic collaborators this year, including United Laboratories International and Deep Apple Therapeutics.

Eli Lilly and Company drives growth with innovative diabetes and obesity drugs, expanding portfolios, and R&D strength. Click for more on LLY stock prospects.

Advocates are pushing back against Tricare's plan to end its coverage of weight-loss drugs for Tricare for Life beneficiaries ...

GoodRx reports tips for safely switching between GLP-1 medications due to side effects, insurance changes, or treatment goals ...

Elli Lily said on Tuesday that its daily weight loss pill helped patients lose weight, specifically those with obesity and ...

Novo Nordisk has taken the next step in selling its drugs directly to patients by pointing them to telehealth providers that ...

Weight loss drugs like Ozempic and Wegovy have been the topic of much recent research. A new study from Levity found a ...

Right now, the only oral GLP-1 drug is Novo Nordisk’s Rybelsus, a pill form of semaglutide approved only for diabetes, not obesity. Novo is pursuing a higher-dose version aimed at weight loss, which ...

In separate announcements, Form Health and 9amHealth said they would provide patients seeking support for obesity care with ...